NRC-AN-019

Catalog No. A13562

NRC-AN-019是Bcr-Abl蛋白-酪氨酸激酶的口服酪氨酸激酶抑制剂(TKI)。NRC-AN-019在抑制MDAMB231和HTB20/BT474细胞的血管生成潜力和增殖方面更有效。
Catalog Num A13562
M. Wt 517.431
Formula C25H17F6N5O
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 879507-25-2
Synonyms AN019, AN 019, NRC-an-019
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
NRC-AN-019是Bcr-Abl蛋白-酪氨酸激酶的口服酪氨酸激酶抑制剂(TKI)。NRC-AN-019在抑制MDAMB231和HTB20/BT474细胞的血管生成潜力和增殖方面更有效。
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 19.33 mL 96.63 mL 193.26 mL
0.5 mM 3.87 mL 19.33 mL 38.65 mL
1 mM 1.93 mL 9.66 mL 19.33 mL
5 mM 0.39 mL 1.93 mL 3.87 mL

*The above data is based on the productmolecular weight 517.431. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.